Abstract
As opposed to the testing of safety, the testing of the efficacy of antibiotics in animals is not specified in any directives or guidelines and not explicitly required by regulatory authorities. There exists, however, no doubt that in the evaluation of new compounds testing of both safety and efficacy forms an essential link between in vitro tests and clinical trials. It is inconceivable that clinicians would be prepared to conduct a trial in patients without evidence of the efficacy of the antibiotic in question in an appropriate animal model of infection. Both the models for testing safety and those for testing efficacy suffer from a number of shortcomings. If investigators are aware of these deficiencies and take them into account when interpreting the results, the predictive value of the models can be significantly enhanced.
Similar content being viewed by others
References
Domagk G: Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Deutsche Medizinische Wochenschrift 1935, 61: 250–253.
Chain E, Florey HW, Gardner AD, Heatley NG, Jennings MA, Orr-Ewing J, Sanders AG: Penicillin as a chemotherapeutic agent. Lancet 1940, 239: 226–228.
Abraham EP: Fleming's discovery. Reviews of Infectious Diseases 1980, 2: 140–141.
Zak O, Sande MA (ed): Experimental models in antimicrobial chemotherapy. Volumes 1–3. Academic Press, London, 1986.
Miller AK: In vivo evaluation of antibacterial chemotherapeutic substances. Advances in Applied Microbiology 1971, 14: 151–183.
O'Grady F: Animal models in the assessment of antimicrobial agents. Journal of Antimicrobial Chemotherapy 1976, 2: 1–3.
Barza M: A critique of animal models in antibiotic research. Scandinavian Journal of Infectious Diseases 1978, 14, Supplement: 109–117.
Bergeron MG: A review of models for the therapy of experimental infections. Scandinavian Journal of Infectious Diseases 1978, 14, Supplement: 189:206.
Zak O: Scope and limitations of experimental chemotherapy. Experientia 1980, 36: 479–483.
Zak O: Usefulness and limitations of animal models in the study of opportunistic nonbacterial infections. In: Klastersky J (ed): Infections in cancer patients. Raven Press, New York, 1982, p. 24–45.
US Food and Drug Administration: Nonclinical laboratory practice regulations. Federal Register 1978, 43: 59986–60025. US Department of Health, Education and Welfare, Washington, DC, 1978.
Bruhin H: Principles of animal care. In: Zak O, Sande MA (ed): Experimental models in antimicrobial chemotherapy. Volume 1, Academic Press, London, 1986, p. 7–18.
Schweizerische Akademie der Wissenschaften und Schweizerische Naturforschende Gesellschaft: Ethische Grundsätze und Richtlinien für wissenschaftliche Tierversuche. Schweizerische Ärztezeitung/Bulletin des Médecins Suisses 1983, 64: 943–946.
Council of Europe: European convention for the protection of vertebrate animals used for experimental and other scientific purposes. European Treaty Series No. 123. Council of Europe, Strasbourg, 1986, p. 1–51.
Commission of the European Communities: Commission directive of 18 November 1987, Part B. Methods for the determination of toxicity. Official Journal of the European Communities, 30 May 1988, p. 4–87.
Organisation for Economic Co-operation and Development: OECD guidelines for testing of chemicals, Section 4. Health effects. OECD, Paris, 1987.
Wachsmuth ED, Thomann P: Testing for renal tolerability: cefsulodin in rats and rabbits. In: Bach PH, Bonner FW, Bridges JW, Lock EA (ed): Nephrotoxicity: assessment and pathogenesis. John Wiley, Chichester, 1982, p. 498–503.
Zak O: Experimental bacterial osteomyelitis in the evaluation of antibiotics. In: Ishigami J (ed): Recent advances in chemotherapy. University of Tokyo Press, 1985, p. 80–82.
World Health Organization, Regional Office for Europe: Guidelines for the clinical investigation of antibacterial drugs 2. Preclinical testing. Revised draft. Copenhagen, June 1986, p. 3.
Zak O, Sande MA: Introduction: the role of animal models in the evaluation of new antibiotics. In: Zak O, Sande MA (ed): Experimental models in antimicrobial chemotherapy. Volume 1. Academic Press, London, 1986, p. 1–5.
Nishino T, Zak O: Systemic infection in mice: a first-line screening model in the evaluation of new antibiotics. In: Ishigami J (ed): Recent advances in chemotherapy. University of Tokyo Press, 1955, p. 72–74.
Hajdu R, Hayase K, Sundelof J, Kropp H, Kahan F: Cilastatin-sensitive lactamase active on carbapenem and penem antibiotics in the lung of rodents. In: Ishigami J (ed): Recent advances in chemotherapy. University of Tokyo Press, 1985, p. 1211–1212.
Goble, FC, Konopka EA: Sex as a factor in infectious diseases. Transactions of the New York Academy of Sciences (Series II) 1973, 35: 325–346.
Harter DH, Petersdorf RG: A consideration of the pathogenesis of bacterial meningitis: review of experimental and clinical studies. Yale Journal of Biology and Medicine 1960, 32: 280–309.
Scheld WM: Experimental animal models of meningitis. In: Zak O, Sande MA (ed): Experimental models in antimicrobial chemotherapy. Volume 1. Academic Press, London, 1986, p. 139–186.
Norrby R: A review of penetration of antibiotics into CSF and its clinical significance. Scandinavian Journal of Infectious Diseases 1978, 14, Supplement: 296–309.
Sande MA: Factors influencing the penetration and activity of antibiotics in experimental meningitis. Journal of Infection 1981, 3, Supplement 1: 33–38.
Scheld WM: Evaluation of new antibiotics with experimental models of bacterial meningitis. In: Ishigami J (ed): Recent advances in chemotherapy. University of Tokyo Press, 1985, p. 83–86.
Nolan CM, Ulmer WC: Penetration of cefotaxime and moxalactam into cerebrospinal fluid of rabbits with experimentally inducedEscherichia coli meningitis. Reviews of Infectious Diseases 1982, Supplement: 396–400.
Ernst JD, Sande MA: Selected examples of failure of in vitro testing to predict in vivo response to antibiotics. In: Sabath LD (ed): Action of antibiotics in patients. Hans Huber, Bern, 1982, p. 68–73.
Zak O, Sande MA: Correlation of in vitro antimicrobial activity of antibiotics with results of treatment in experimental animal models and human infection. In: Sabath LD (ed): Action of antibiotics in patients. Hans Huber, Bern, 1982, p. 55–67.
Scheld WM, Sande MA: Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. Journal of Clinical Investigation 1983, 71: 411–419.
Scheld WM, Täuber MG, Zak O, Sande MA: The influence of dosing schedules and cerebrospinal fluid bactericial activity on the therapy of bacterial meningitis. Journal of Antimicrobial Chemotherapy 1985, 15, Supplement A: 303–312.
Lebel MH, Hoyt MJ, McCracken GH: Comparative efficacy of ceftizoxime and cefuroxime for treatment of bacterial meningitis. Journal of Pediatrics 1989, 114: 1049–1054.
Täuber MG, Khayam-Bashi H, Sande MA: Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. Journal of Infectious Diseases 1985, 151: 528–534.
Syrogiannopoulos GA, Olson KD, Reisch JS, McCracken GH: Dexamethasone in the treatment of experimentalHaemophilus influenzae type b meningitis. Journal of Infectious Diseases 1987, 155: 213–219.
Kadurugamuwa JL, Hengstler B, Zak O: Effects of antiinflammatory drugs on arachidonic acid metabolites and cerebrospinal fluid proteins during infectious pneumococcal meningitis in rabbits. Pediatric Infectious Diseases Journal 1987, 6: 1153–1154.
Tuomanen E, Hengstler B, Rich R, Bray MA, Zak O, Tomasz A: Nonsteroidal antiinflammatory agents in the therapy of experimental pneumococcal meningitis. Journal of Infectious Diseases 1987, 155: 985–990.
Kadurugamuwa JL, Hengstler B, Zak O: Cerebrospinal fluid protein profile in experimental pneumococcal meningitis and its alteration by ampicillin and anti-inflammatory agents. Journal of Infectious Diseases 1989, 159: 26–34.
Norden CW: Experimental osteomyelitis. I: A description of the model. Journal of Infectious Diseases 1970, 122: 410–418.
Zak O, Zak F, Rich F, Tosch W, Kradolfer F, Scheld WM: Experimental staphylococcal osteomyelitis in rats: Therapy with rifampin and cloxacillin, alone or in combination. In: Periti P, Grassi GG (ed): Current chemotherapy and immunotherapy. American Society for Microbiology, Washington, 1982, p. 973–974.
Deysine M, Rosario E, Isenberg H: Acute hematogenous osteomyelitis: an experimental model. Surgery 1976, 79: 97–99.
Mader JT, Wilson KJ: Models of osteomyelitis. In: Zak O, Sande MA (ed): Experimental models in antimicrobial chemotherapy. Volume 2. Academic Press, London, 1986, p. 155–173.
Norden CW: Lessons learned from animal models of osteomyelitis. Reviews of Infectious Diseases 1988, 10: 103–110.
Zak O, Zak F, Scheld WM: Efficacy of rifampicin combined with cloxacillin in experimental chronic staphylococcal osteomyelitis in rats. In: Spitzy KH, Karrer K (ed): Proceedings of the 13th International Congress of Chemotherapy. Vienna, 1983, PS 4.6/6, p. 111/12–111/15.
Norden CW: Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Reviews of Infectious Diseases 1983, 5, Supplement 3: 491–494.
Norden CW, Fierer J, Bryant RE: Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. Reviews of Infectious Diseases 1983, 5, Supplement 3: 495–501.
Waldvogel FA, Vasey H: Osteomyelitis: the past decade. New England Journal of Medicine 1980, 99: 569–571.
Maurer M, Kradolfer F: Chemotherapy with bicozamycin in piglets with acute enterotoxigenicEscherichia coli diarrhea. In: Periti P, Grassi GG (ed): Current chemotherapy and immunotherapy. American Society for Microbiology, Washington, 1982, p. 260–261.
Ericsson CD, Du Pont HL, Sullivan P, Galdindo E, Evans DG, Evans DJ: Bicozamycin, a poorly absorbable antibiotic, effectively treats travelers' diarrhea. Annals of Internal Medicine 1983, 98: 20–25.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zak, O., O'Reilly, T. Animal models as predictors of the safety and efficacy of antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 9, 472–478 (1990). https://doi.org/10.1007/BF01964286
Issue Date:
DOI: https://doi.org/10.1007/BF01964286